Craig Portell, MD, shares the future clinical impact of his work, the complexity and diversity of lymphoma subtypes, and what drew him to UVA Health.
Tag: blood cancer
Our program includes a multidisciplinary team, access to innovative treatments, and a commitment to research.
When Jillian's leukemia relapsed, CAR T-cell therapy was her best option. Here's how the use case for CAR T in treating children's cancer is expanding.
UVA Cancer Center researchers lead acute myeloid leukemia (AML) discovery that could pave the way for improved treatments and patient outcomes.
Thomas Loughran, MD, reveals the most intriguing clinical applications for his LGL and acute myeloid leukemias research.
UVA researchers are evaluating a novel CAR T-cell in order to expand this therapy to treat patients with untreatable lymphomas.